Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2010 / Cilt: 20 - Sayı: 3

Secondary Cancers

İkincil Kanserler

Pages
190–199
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Besides effective screening methods and preventive strategies should be devel oped to risk for second primary cancers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Secondary cancer refers to a new primary cancer that is caused by previous cancer treatment, or a new primary cancer in a person with a history of cancer.
📊
Key Findings & Data:Because of the improvement of diagnosis and treatment for childhood and adult cancers have improved over several decades, the proportion of cancer survivors within the general population increases every years.
💡
Conclusion & Impact:Besides effective screening methods and preventive strategies should be devel oped to risk for second primary cancers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Secondary cancer refers to a new primary cancer that is caused by previous cancer treatment, or a new primary cancer in a person with a history of cancer. Because of the improvement of diagnosis and treatment for childhood and adult cancers have improved over several decades, the proportion of cancer survivors within the general population increases every years. The prolongation of survival in increasing numbers of patients, identification and quantification of the late effects of cancer and its therapy have become critical. One of the most serious events experienced by cancer survivors is the diagnosis of a new cancer. Childhood and adult cancer survivors have an increased risk of developing second and subsequent cancers that varies by host factors (genetics, immune function, hormonal status); primary cancer therapy; environmental exposures; and lifestyle factors. An improved understanding of therapy-related second malignancies can guide alterations in regimens to minimize cytotoxic treatment exposure. Besides effective screening methods and preventive strategies should be devel oped to risk for second primary cancers.

Özet

Kanser tedavisi almış veya kanser öyküsü olan bir hastada, histopatolojik olarak birincil tümörden farklı, yeni bir malign hastalık ortaya çıkmasına ikincil kanser denir. Son yıllarda erişkin ve çocukluk çağı kanserlerinin tanı ve tedavisindeki iyileşmeler nedeniyle toplumda kanserden sağ kalanların sıklığı artmaktadır. Yaşam süresi uzayan hasta sayısının artması ile, kanser tedavisine bağlı geç etkilerin belirlenmesi ve bunların tedavileri oldukça önemli hale gelmiştir. Sağ kalan hastalarda görülen en ciddi yan etkilerden birisi yeni-ikincil kanser gelişimidir. Hastanın genetik, immunolojik, hormonal özellikleri, birin cil kanser nedeniyle uygulanan tedaviler, çevresel faktörler ve hastanın yaşam biçimi, ikincil kanser gelişme riskini etkileyen faktörlerdir. Tedavi ile ilişkili ikincil kanser gelişiminin daha iyi anlaşılabilmesi tedavi rejimlerinde sitotoksik ilaçların kullanımına rehberlik edebilir. İkincil primer kanser riskleri için etkin tarama yöntemleri ve koruyucu önlemler geliştirilmelidir.

🔖

Cite This Article

ÇEÇEN, E., BOLAMAN, A. Z. (2010). Secondary Cancers. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 20 - Sayı: 3, 190–199. https://ajindex.com/articles/323216

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Travis LB, Rabkin CS, Brown LM, et al. Cancer sur vivorship-genetic susceptibility and second primary cancers: Research strategies and recommendations. J Natl Cancer Inst 98: 15-25, 2006
  2. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and ado lescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 19: 3163-3172, 2001. 3. http://seer.cancer.gov/publications/mpmono/ MPMonograph_complete.pdf (Access date: 10/06/2009)
  3. Li FP, Cassady JR, Jaffe N. Risk of second tumors in survivors of childhood cancer. Cancer 35: 1230-1235, 1975
  4. Neglia JP, Friedman DL, Yasui Y, et al. Second malig nant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Can cer Inst 93: 618-629, 2001
  5. Olsen JH, Garwicz S, Hertz H, et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncol- ogy Association of the Nordic Cancer Registries. BMJ 307: 1030-1036, 1993
  6. Travis LB. Therapy-associated solid tumors. Acta Oncol 41: 323-333, 2002
  7. Bhatia S, Blatt J, Meadows A. Late effects of child hood cancer and its treatment. In Principles and Prac tice of Pediatric Oncology. 5 ed. Pizzo P PD, Ed. Philadelphia, Lippincott Williams & Wilkins, 2006, p. 1490-1514
  8. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem- cell transplantation for lymphoid malignancies. J Clin Oncol 12: 2527-2534, 1994. 10. van Leeuwen FE TL. Second cancers. In Cancer: prin ciples and practice of oncology. 7th ed. DeVita VT HSRS, Ed. Philadelphia, Lippincott Williams &Wilkins, 2005, p. 2572-2602
  9. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334: 745-751, 1996
  10. Wong FL, Boice JD, Jr., Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278: 1262-1267, 1997
  11. Zang EA, Barrett NO, Cohen LA. Differences in nutri tional risk factors for breast cancer among New York City white, Hispanic, and black college students. Ethn Dis 4: 28-40, 1994
  12. Hawkins MM, Wilson LM, Burton HS, et al. Radiother apy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88: 270-278, 1996
  13. Breslow NE, Takashima JR, Whitton JA, et al. Second